1. Home
  2. SON vs HAE Comparison

SON vs HAE Comparison

Compare SON & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$44.39

Market Cap

4.3B

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$79.45

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SON
HAE
Founded
1899
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
3.7B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
SON
HAE
Price
$44.39
$79.45
Analyst Decision
Strong Buy
Buy
Analyst Count
7
9
Target Price
$56.83
$88.38
AVG Volume (30 Days)
886.5K
712.4K
Earning Date
02-17-2026
02-05-2026
Dividend Yield
4.86%
N/A
EPS Growth
116.52
42.54
EPS
6.30
3.44
Revenue
$7,114,053,000.00
$1,327,850,000.00
Revenue This Year
$45.34
N/A
Revenue Next Year
N/A
$6.01
P/E Ratio
$23.56
$23.33
Revenue Growth
67.86
N/A
52 Week Low
$38.65
$47.32
52 Week High
$50.09
$87.32

Technical Indicators

Market Signals
Indicator
SON
HAE
Relative Strength Index (RSI) 69.19 53.54
Support Level $42.96 $79.41
Resistance Level $44.10 $81.27
Average True Range (ATR) 0.66 1.67
MACD 0.09 -0.91
Stochastic Oscillator 97.01 14.94

Price Performance

Historical Comparison
SON
HAE

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: